◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound SKIP-FOR-NOW HIGH

Fadogia Agrestis

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

"Fadogia agrestis sits in a uniquely shallow evidence puddle: ZERO human RCTs as of mid-2026, all testosterone claims rest on Yakubu 2005 (a 5-day rat study, n=20-something male albino rats, aqueous stem extract at 18-100 mg/kg) and a follow-up Yakubu 2008 28-day rat study that found dose-dependent IRREVERSIBLE testicular damage at 50-100 mg/kg. The viral popularization came from Andrew Huberman 2021-2022 podcast appearances (Huberman Lab + Joe Rogan), which moved a folkloric Nigerian aphrodisiac into the biohacker default stack with no human safety data backing the 600 mg/day dose he reported using. The 2024 Yakubu (already 2009 in publication) mode-of-cellular-toxicity paper documented lipid-peroxidation-driven membrane disruption in rat liver + kidney at 50-100 mg/kg over 28 days. A 2025 American Thoracic Society case report (Coalson et al., AJRCCM 211:A3862) documented a 51yo male who died of biventricular failure + ARDS + DIC after concurrent use of Fadogia + trimethylglycine + anastrozole + AAS — Fadogia is one of several causal candidates but the case is the first published fatality flagged to it. For Dylan (20yo MMA athlete, peak endogenous testosterone, no documented hypogonadism), the upside is essentially zero (T already at ceiling), the downside is non-trivial (rat hepatotoxicity + 1 fatality case + complete absence of human safety envelope), and the marketing-vs-evidence gap is dishonest enough to warrant a confident skip. SKIP-FOR-NOW because (a) zero human evidence, (b) demonstrated rat hepato/nephrotoxicity at doses overlapping the human-extrapolated supplement range, (c) one published fatality with Fadogia in the polypharmacy, (d) sourcing is unstandardized (10:1 vs 50:1 vs whole-plant extracts with no enforceable identity), (e) cleaner T-modulating tools exist for the rare archetype that needs them (Rx TRT with monitoring, dietary fat + zinc + sleep optimization). Verdict would change to NEEDS-FURTHER-DATA only if a Phase 2 RCT in hypogonadal men published with ≥3-month safety follow-up + LFT/renal monitoring; verdict will NEVER reach PRIMARY-PICK for archetypes with normal baseline T."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan (20yo, MMA athlete + business owner, peak endogenous T, no hypogonadism diagnosis)
    SKIP-FOR-NOW

    HIGH confidence. At 20, total T is at or near lifetime peak (Western reference range ~600-1000+ ng/dL in healthy 18-25 yo males). LH-axis stimulation provides no realistic incremental benefit — the HPG axis is already running near its set point. Downside exposure: rat hepatotoxicity at the BSA-equivalent human dose (600 mg), rat testicular toxicity at the BSA-equivalent 300-600 mg range, one published fatality case in a different polypharmacy context, sexual side-effect community signal, zero human RCTs to anchor any of this. No realistic edge case unhides the verdict. Reassess only if a Phase 2 RCT publishes in hypogonadal men with safety follow-up — and even then, Dylan is not the target population.

  • Athletic male 18-35 with normal T
    SKIP

    unless documented low-T with failed mainstream Rx pathway. Same logic as Dylan — peak T axis means no benefit to expect, full downside to absorb. Mainstream tools (sleep, training, diet, body comp, alcohol reduction) cover the upside more reliably with zero hepatotoxic risk.

  • Huberman-listener (any age) considering Fadogia because the podcast popularized it
    HONEST FRAME

    The honest read is: Huberman built a personal n=1 protocol on rat data, popularized it before human evidence existed, and the supplement industry monetized the gap. Four years on, the human-evidence vacuum is unchanged but the case-report literature has begun documenting harm (Coalson 2025). The case for skipping is stronger now than when Huberman first mentioned it. If a user wants T support, mainstream tools (sleep, weight, alcohol, dietary fat, vitamin D status, zinc status, total training load) deliver more reliable T modulation with zero hepatotoxicity tail.

  • 30-50yo M with suspected low-T but undiagnosed
    GET BLOODWORK FIRST

    Total T, free T, LH, FSH, SHBG, estradiol-sensitive, AM cortisol, TSH, ferritin, vitamin D. If low-T confirmed, Rx pathway (clomid/enclomiphene/HCG/TRT) with endocrinologist supervision is the appropriate response — not unregulated herbal with one published fatality case and zero RCTs. Fadogia is not the answer to a real clinical question.

  • 30-50yo M with confirmed mild low-T (T 250-400 ng/dL) who refuses Rx pathway
    SKIP-FOR-NOW

    remains the cleanest call, but this is the narrow archetype where someone might still self-experiment. If they will not be talked out of it: 300 mg/day at most, 8-week max cycle, baseline + 4-week + 8-week LFTs and renal panel, baseline + 8-week T + LH + FSH + E2 to verify mechanism plausibility, hard stop on any LFT elevation >1.5× ULN. Honest framing: this is harm-reduction, not endorsement.

  • Liver disease (any, including NAFLD / fatty liver, hep B/C, prior hepatotoxic-drug exposure)
    HARD BLOCK

    Lipid-peroxidation rat hepatotoxicity signal converts to clinically unacceptable risk in compromised baseline.

  • Active or recent AAS cycle user
    HARD BLOCK

    Coalson 2025 fatal case is the single most important piece of human Fadogia data. The combined hepatotoxic + cardiotoxic + HPG-perturbing load is the documented kill pathway. There is no protocol where Fadogia is added to an AAS cycle and the risk profile is acceptable.

  • Prostate cancer history, active BPH with significant symptoms
    HARD BLOCK

    Any T-elevating intervention is contraindicated in this context.

  • Cardiovascular disease, recent MI, uncontrolled HTN, cardiomyopathy
    STRONG CAUTION

    Coalson 2025 patient had baseline HTN/hyperlipidemia; whether Fadogia contributed independently to the cardiac collapse is unanswerable from one case, but the precautionary default is block.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    No mechanism for benefit; full downside exposure during a period when liver and renal function are stress-tested. Archetype summary: No archetype where the evidence supports a PRIMARY-PICK or even a confident OPTIONAL-ADD verdict. The maximum reachable verdict on current data is NEEDS-FURTHER-DATA for narrow harm-reduction contexts in confirmed-low-T men who refuse Rx; everyone else lands on SKIP-FOR-NOW.

▸ Subjective experience (deep)

At Huberman-popularized dose (600 mg/day, single dose, often AM):

  • Onset: Unknown — no human PK. Anecdotal reports describe "noticing nothing for the first 1-3 weeks," then either an emergent libido increase, an increase in morning erections, or a subjective energy/aggression lift. Consistent with a slow-onset hormonal modulator rather than an acute stimulant.
  • Peak: No discernible acute peak in user reports — Fadogia does not produce a "felt dose," which is part of why dose escalation is common (users assume more is doing more).
  • Plateau: Reports converge on weeks 3-8 as the "effect window" if effect is present. Users who continue beyond 8-12 weeks often report tolerance — gradual loss of the libido lift.
  • Reports of nothing: Common. A meaningful subset of users (especially young men with normal baseline T) describe no subjective effect at any dose over 8 weeks.

Characteristic reported effects (community-aggregate, low confidence):

  • Increased libido / morning erections (16/110 dopamine.club, top side benefit)
  • Subjective energy lift (13/110)
  • Mood elevation / increased aggression / "more dominant" subjective state (13/110)
  • Muscle pump / training intensity perception (10/110)
  • Improved recovery between training sessions (9/110)

Characteristic adverse subjective experience:

  • Paradoxical sexual side effects (anorgasmia, ED) — 5/110 dopamine.club. Often emerges around week 6-12 of continuous use; consistent with HPG axis disruption signature seen with other LH-axis-acting compounds.
  • Anxiety (5/110)
  • Emotional blunting (6/110) — "feeling less alive" / "robot mode" — uncommon but enough to register
  • Insomnia (3/110)
  • Fatigue (3/110), often emerging during cycle-off phase consistent with HPG-axis recovery dynamics

Tolerance trajectory: Most users either feel nothing throughout or feel something for 3-8 weeks that fades by week 8-12. The Huberman-recommended cycling protocol (8 weeks on / 2-4 weeks off; or 12 on / 4 off) is a community workaround for this fade, not an evidence-based design.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Anecdotal — most users report fade of subjective effect (if any) over 8-12 weeks. Mechanism would be HPG-axis adaptation: chronic LH-axis stimulation → negative-feedback recalibration → blunted T response despite continued dosing. Consistent with the broader observation that LH-driven T elevation is self-limiting because the HPG axis is exquisitely feedback-controlled.
  • Recommended cycle (Huberman convention, no evidence basis): 8 weeks on / 2-4 weeks off, or 12 on / 4 off. No human trial has validated any cycling protocol. The rationale is plausible (allow HPG-axis recovery, allow hepatic-toxicity recovery, restore subjective effect) but the specific durations are made up.
  • Reset protocol: Not characterized. Most users who cycle off describe normalization of baseline within 2-4 weeks; some report a 4-8 week post-cycle slump consistent with transient HPG-axis suppression.
  • Cross-tolerance: With Tongkat Ali (overlapping LH-axis mechanism), other testosterone-supportive herbs (Ashwagandha, Tribulus). Practical implication: stacking these together does not generate additive T elevation; it generates additive hepatotoxic + HPG-axis-modulating load with minimal incremental benefit.
  • Permanent receptor or HPG-axis impact? Unknown. No long-term human follow-up data. The Yakubu 2008 rat finding of irreversible testicular damage at 50-100 mg/kg / 28 days is the salient concern; the question of whether equivalent human exposure causes equivalent harm is unanswered and unlikely to be answered absent a controlled human trial with reproductive endpoints.
▸ Stacking deep dive

Synergistic with (in the sense of "commonly co-administered" — synergy is unproven)

  • Tongkat Ali / Eurycoma longifolia (74/110 dopamine.club Fadogia users). The dominant pairing. Overlapping mechanism (both putatively LH-axis), so the synergy claim is weak — more likely the pairing reflects Huberman-stack co-promotion than additive pharmacology. Hepatotoxic-load risk: Tongkat Ali has its own 2024 case-report hepatotoxicity signal (Kaliounji); combining two herbal hepatotoxicants is a higher risk than using either alone.
  • Vitamin D3, Zinc, Boron, Vitamin K — these are appropriate baseline micronutrients for endogenous T optimization regardless of Fadogia. Their utility is independent of Fadogia; stacking does not augment Fadogia's effect, but Fadogia stacking does not interfere with their utility.
  • Creatine monohydrate — common gym stack pairing; no pharmacological interaction; creatine works regardless of Fadogia status.
  • Ashwagandha — different mechanism (cortisol modulation, GABAergic anxiolysis); the pairing rationale is "lower cortisol + raise T," but ashwagandha's T effect is modest in humans and Fadogia's is unproven. Practically: ashwagandha is the more evidence-supported half of this stack.
  • Shilajit — mineral-rich exudate; weak human evidence for T modulation; combination is biohacker convention not evidence-based.

Avoid stacking with

  • Anabolic androgenic steroids (AAS) — HARD AVOID. Coalson 2025 fatality case. The hepatotoxic + cardiotoxic + HPG-axis-perturbing load combines in ways the published case literature is just beginning to document. Hard contraindication regardless of dose.
  • Aromatase inhibitors (anastrozole, letrozole, exemestane) — HARD AVOID in supplemental context. Coalson 2025 case. The use case where someone is on an AI AND wants Fadogia is implicitly an AAS-cycle adjunct, which is the highest-risk possible context.
  • Other hepatotoxic herbs — Black Cohosh, Kava, Green Tea Extract (high-dose EGCG), high-dose niacin, comfrey, Tongkat Ali at high doses. Cumulative hepatotoxic burden.
  • Hepatotoxic pharmaceuticals — statins (already on dose ceiling), isoniazid, acetaminophen at chronic high doses, valproate, methotrexate. Cumulative hepatic load.
  • Alcohol (chronic moderate-to-heavy) — additive hepatocellular stress.
  • DHEA / pregnenolone at high doses — overlapping androgenic load, mostly redundant.
  • SARMs (RAD-140, LGD-4033, etc.) — overlapping androgenic + hepatic load with weaker safety data than even Fadogia. Combination context is gym-culture polypharmacy, not biohacking.

Neutral / safe co-administration

  • Standard micronutrients (D3, K2, Mg, Zn, B-vitamins, omega-3) — no known interaction.
  • Caffeine, L-theanine, common nootropics (racetams, alpha-GPC, modafinil) — no known interaction at the pharmacology level; Fadogia adds no cognitive value here.
  • Standard training nutrition (creatine, beta-alanine, whey protein) — no known interaction.
▸ Drug interactions deep dive

Pharmacological note: No published human drug-interaction data exist for Fadogia agrestis. Everything in this section is theoretical, inferred from mechanism or stack-context safety signals.

  • CYP induction/inhibition profile: Uncharacterized. The crude extract likely contains multiple phytochemicals with potential CYP3A4 / CYP2D6 effects (typical of saponin- and alkaloid-rich herbal extracts), but no formal CYP screen has been published. Assume unknown CYP interactions are possible.
  • Anticoagulants / antiplatelets: Uncharacterized. The phytochemistry includes anthraquinones which have variable platelet effects in other Rubiaceae extracts; theoretical caution with warfarin, DOACs, aspirin.
  • Hormonal contraception: Theoretical concern if Fadogia ever induces CYP3A4 (would reduce ethinyl estradiol exposure); unstudied. Not directly relevant in male users but relevant to clinical advice generally.
  • Antihypertensives: Uncharacterized. The Coalson 2025 case patient had baseline HTN; whether Fadogia contributed to cardiovascular destabilization independent of AAS load is unknowable from the case.
  • Other testosterone-axis pharmacology: DO NOT COMBINE with exogenous testosterone (TRT or AAS), HCG, clomiphene, enclomiphene, anastrozole, letrozole, exemestane, or SARMs. The combination is the polypharmacy pattern at the center of the 2025 fatal case.
  • Hepatotoxic drugs / herbs: Avoid co-administration with any agent on the LiverTox list of probable hepatotoxicants. Cumulative oxidative stress on hepatocyte membranes is the rat-data-inferred toxicity pathway, and combining hepatotoxic agents predictably worsens this.
  • Alcohol: Theoretical caution. No specific data. Practically: chronic Fadogia + chronic moderate alcohol is a hepatic-stress combination worth avoiding.
▸ Pharmacogenomics
  • No actionable Fadogia-specific PGx data exists. Zero papers, zero variants associated with response or toxicity. Speculation in this section is hypothesis-only.
  • CYP3A4 / CYP2D6 / CYP2C19 polymorphisms — could in principle modulate hepatic clearance of phytochemicals in the Fadogia extract, but specific substrates and CYP routes are uncharacterized.
  • HPG-axis-related variants (AR, SHBG, CYP19A1/aromatase): Variants in androgen receptor sensitivity (CAG repeat length), SHBG promoter, or aromatase activity could plausibly modulate Fadogia response — a man with high aromatase activity would convert any T elevation rapidly to estradiol, blunting the perceived benefit and possibly worsening sexual side effects via E2 elevation. Speculative.
  • Hepatotoxicity-related variants (NAT2, GST, SOD2): Variants affecting oxidative-stress handling capacity could in principle alter individual hepatotoxic susceptibility to Fadogia. The rat lipid-peroxidation mechanism (Yakubu 2009) is exactly the kind of insult that low antioxidant capacity would amplify. Speculative.
  • Practical takeaway for Dylan (23andMe results pending June 2026): Even if PGx looks favorable on theoretical handling, the verdict does not change. Absence of evidence is not evidence of safety in a compound this thinly studied.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Amazon OTC capsule Double Wood Supplements, Toniiq, Nutricost, Micro Ingredients $20-40 / 60-180 capsules at 300-600 mg Medium — third-party tested for heavy metals + microbiology by reputable brands, but extract-ratio standardization is voluntary and identity testing is rarely COA-verified. 10:1 stem extract is the de facto US-OTC standard. No FDA enforcement of identity. "600 mg" on a label can mean wildly different pharmacological exposure depending on extract ratio.
Bulk powder Nootropics Depot (historical, discontinued some lines), Greenjeeva, Barlowe's $30-60 / 50-100g Medium-High for the reputable bulk suppliers (Greenjeeva publishes COA + heavy metals + microbial testing) Bulk allows ratio-verified sourcing; consumer-grade powder still requires user trust in supplier.
Compounded / pre-mixed stack "Test Boost" stacks combining Fadogia + Tongkat + Zinc + Boron $40-90 / bottle Low-Medium — proprietary blends frequently hide individual doses; quality varies; some "T-booster" stacks have been caught with undisclosed sildenafil-analog adulterants The Fadogia + Tongkat marketing convention; convenience comes at identity-verification cost.
Whole-stem powder Specialty herb sellers, occasional Etsy/Amazon listings $15-40 / 100g Low-Medium Whole-plant material from West African suppliers; identity verification difficult; heavy-metal risk higher than purified extract.
Pharmaceutical-grade Does not exist. No pharmaceutical-grade Fadogia is available. — — This is a key sourcing fact: Fadogia is never an Rx product anywhere in the world. The entire supply is dietary-supplement-grade.

Sourcing-difficulty rating: easy — Fadogia is widely available on Amazon, supplement specialty sites, and direct-to-consumer. Sourcing is not the problem. The problem is that the molecule and its evidence base, not the supply, is the limiting factor.

Specific brand-quality notes:

  • Double Wood Supplements — Third-party tested, 600 mg per serving, Amazon-distributed. The de facto Huberman-listener default.
  • Toniiq — Premium-positioned, 50:1 extract claims (verify with COA); higher price tier.
  • Nutricost / Micro Ingredients — Budget tier; less identity-verification documentation.
  • Greenjeeva (bulk B2B) — COA-published bulk supplier; if a user is going to take Fadogia despite this verdict, this is the cleanest sourcing tier.

Key sourcing point for Dylan: Sourcing is solvable trivially via Amazon. The verdict is "should not take it," not "cannot get it." Easy sourcing is, if anything, a downside — the low friction makes the marketing-vs-evidence gap more dangerous because the supplement is on every Amazon checkout.

▸ Biomarkers to track (deep)

If taken anyway (against this verdict's recommendation):

Baseline (before starting)

  • Total testosterone, free testosterone, SHBG, LH, FSH — establishes whether you're in a clinical state where Fadogia even has a theoretical use case. If T > 500 ng/dL, the answer is no.
  • Estradiol (sensitive LC-MS/MS assay; standard immunoassay E2 is unreliable in men) — baseline for monitoring aromatization shifts.
  • ALT, AST, GGT, alkaline phosphatase, total bilirubin — hepatic baseline.
  • BUN, creatinine, eGFR — renal baseline.
  • CBC + ferritin + lipids — general health baseline; hematocrit watch for AAS-mimic erythrocytosis.
  • PSA if >30 — prostate baseline before T-elevating intervention.
  • Sexual function baseline (libido VAS, morning-erection frequency, IIEF-5 if relevant) — pre-intervention reference for tracking paradoxical sexual side effects.

During use

  • Weeks 4 + 8: Repeat LFTs + renal panel. Any ALT or AST rise >1.5× ULN → discontinue immediately, recheck in 4 weeks. Any GGT rise >50% → strong caution. Any creatinine rise >0.3 mg/dL → discontinue.
  • Week 8: Repeat T, free T, LH, FSH, E2, SHBG. Mechanism verification — if T is rising and LH is also rising, the LH-axis-stimulation mechanism is at least directionally working. If T is rising but LH is suppressed, the supplement is acting more like a covert AAS (which would be a red flag for adulteration).
  • Week 12 (if cycle continues past 8): Hematocrit + CBC. PSA if >30. Sexual function VAS.
  • Daily / weekly subjective: Libido, mood, anxiety, energy, sleep quality, sexual function. Watch for emerging paradoxical effects in weeks 6-12.

Post-cycle (if cycled off after 8-12 weeks)

  • 4 weeks post: Repeat T, free T, LH, FSH, E2. Verify HPG-axis recovery to baseline. If T has dropped below baseline or LH/FSH are suppressed, the HPG axis is in transient recovery — should resolve in 2-6 weeks but flag for re-test.
  • 8 weeks post: Repeat LFTs + renal panel to confirm full hepatic / renal recovery.
  • Sexual function VAS: Track during cycle-off; emerging or persistent sexual side effects post-discontinuation are the highest-priority signal.

For Dylan specifically (if hypothetically chose to ignore the SKIP verdict)

  • Not recommended. The biomarker pipeline above is harm-reduction scaffolding for the rare archetype that should take Fadogia; Dylan is not in that archetype. The relevant biomarkers for Dylan to track for T optimization are: sleep (Oura), training volume, body fat % (DEXA), 25(OH)D, ferritin, zinc, thyroid panel, AM cortisol — none of which involve a hepatotoxic herbal.
▸ Controversies / open debates Live debate

  1. "Rat data translates to humans for testosterone modulation." Largely false in the specific sense Fadogia advocates use it. Rat HPG-axis pharmacology is qualitatively similar to human HPG-axis pharmacology, so a saponin that stimulates rat LH plausibly stimulates human LH. But the magnitude is wildly inferable, the duration of effect is uncharacterized, the dose-response curve in humans is unmapped, and — critically — the toxicity dose-response curve in humans is also unmapped. The 6× testosterone rise in rats at 100 mg/kg over 5 days does not translate to "humans on 600 mg will see big T jumps." It translates to "we have a plausible mechanism hypothesis worth a Phase 1 trial." That trial has not happened.

  2. "Huberman's personal n=1 from 600 → 800 ng/dL T proves it works." Methodologically weak. Huberman is one person, taking multiple T-supportive interventions simultaneously (Tongkat + Fadogia + sleep optimization + sunlight + training + zinc + vitamin D + boron), with no placebo control, no washout, no replication. Attributing the 200 ng/dL T rise specifically to Fadogia is not justified by the data Huberman discloses. The honest read: this is a high-profile testimonial, not evidence.

  3. "Cycling 5-on/2-off (or 8-on/4-off) makes Fadogia safe." No evidence basis. Cycling protocols are a reasonable hedge against unknown long-term toxicity and HPG-axis suppression, but the specific durations are pulled from podcast convention, not pharmacology. A user cycling 5-on/2-off is still accumulating ~70% of continuous exposure; whatever harms emerge from continuous use likely emerge from this pattern, slower. Cycling is not a safety verification, it is a precaution.

  4. "The LD50 is 5000 mg/kg in rats, so 600 mg in a human is super safe." Confused safety reasoning. LD50 is acute-toxicity endpoint (single-dose lethality). The relevant Fadogia safety concern is chronic dosing toxicity (28-day, 50-100 mg/kg → irreversible testicular damage + hepato/nephro lipid peroxidation). LD50 > 5000 mg/kg tells you Fadogia won't kill a rat in 24 hours at 100 g per person-equivalent. It tells you nothing about what 600 mg/day for 8 weeks does. Confusing acute-LD50 with chronic-safety is the central rhetorical error in pro-Fadogia content.

  5. "Coalson 2025 case was AAS-driven, not Fadogia-driven." Partly true, doesn't acquit Fadogia. The 51yo's biventricular failure profile is consistent with AAS cardiomyopathy. But the authors flagged Fadogia explicitly and called for urgent toxicology research. The honest reading: Fadogia is not causally isolated, but it is a published candidate in a fatal case in a polypharmacy pattern that exists in real users. The case shifts the prior from "no human harms documented" to "first human harm signal published."

  6. "Examine.com says we don't know enough to recommend, which is different from 'don't take it.'" Technically true, practically equivalent. Examine.com's caution framing reflects scientific epistemics — they decline to recommend in the absence of human RCT evidence. The Nootpedia verdict goes one step further: combining (a) zero human evidence, (b) demonstrated rat toxicity, (c) one published fatality case, (d) commercial-marketing dishonesty, the precautionary default for archetypes with no clinical need is don't take it, not wait for evidence and then maybe take it.

  7. Where this verdict might be wrong: A well-conducted Phase 2 RCT in hypogonadal men, with 12-week dosing at 300-600 mg, LFT + renal monitoring, and a confirmed T-elevation effect size > 100 ng/dL with no LFT elevations, would shift the verdict for the documented-low-T archetype to NEEDS-FURTHER-DATA or even OPTIONAL-ADD. Such a trial does not exist, is not registered (clinicaltrials.gov as of May 2026), and is not in any visible academic pipeline. Until it appears, the verdict is robust.

▸ Verdict change log
  • 2026-05-14 — Initial verdict: SKIP-FOR-NOW, HIGH confidence. Promoted from stub-auto to thorough. Rationale: Yakubu 2005 (rat, 5-day, n~24) is the entire mechanistic foundation; Yakubu 2008 + 2009 documented testicular + hepato/nephro toxicity at the human-BSA-equivalent dose range; Coalson 2025 (AJRCCM 211:A3862) is the first published fatality case with Fadogia in the polypharmacy; ZERO human RCTs exist after 4+ years of viral biohacker popularization. For Dylan (20yo, peak endogenous T, MMA athlete), the upside is essentially zero and the downside surface is non-trivial. What would change verdict: publication of a Phase 2 RCT in hypogonadal men with safety follow-up — for that archetype only. Dylan-archetype verdict is unlikely to ever move off SKIP because peak-T 20yo never lands in the use case.
▸ Open questions / gaps Open
  1. Active bioactive identity. Which specific saponin(s) or alkaloid(s) drive the LH-axis effect (if any)? Unknown. No isolated active has been published. Fadogia is a crude-extract pharmacology in 2026, four years into mainstream biohacker use.
  2. Human PK profile. Tmax, t½, AUC, oral bioavailability, protein binding, CYP profile, clearance route — all uncharacterized. No published human PK study exists.
  3. Phase 2 RCT in hypogonadal men. Not registered, not in pipeline as of clinicaltrials.gov May 2026 search. The most important data gap.
  4. HPG-axis recovery dynamics post-cycle in humans. Are there subgroups where cycling-off leads to persistent rather than transient HPG-axis suppression? Unknown.
  5. Long-term hepatic effect at biohacker doses. Whether 5+ years of intermittent 600 mg/day Fadogia produces cumulative hepatic stress, fibrosis, or steatosis is uncharacterized. Will become observable through routine LFT screening over time in the early-adopter cohort but is not formally studied.
  6. Long-term reproductive effect. The Yakubu 2008 irreversible testicular damage finding in rats at 50-100 mg/kg has no human follow-up. Whether any subset of biohackers using 600 mg/day for 8-12-week cycles has developed reduced sperm parameters, testicular atrophy, or impaired fertility is unknown — and the natural-history follow-up isn't going to be funded.
  7. Sourcing identity standardization. No FDA enforcement of "Fadogia agrestis" identity means consumer-grade product is heterogeneous in actual phytochemical content. A bulk-market study testing 20-30 OTC products by HPLC for marker compounds is overdue.
  8. Interaction with AAS in greater detail. Coalson 2025 is one fatal case; the population-level interaction profile of Fadogia + AAS is unstudied. Given the joint-use pattern in gym-culture, this is a meaningful surveillance gap.
  9. Pharmacogenomics of response and toxicity. No published variants. Would take a 200-500 person cohort with bloodwork + 23andMe data to begin to characterize; not in any visible pipeline.

References

Yakubu, Akanji, Oladiji 2005 — Aphrodisiac potentials of aqueous extract of Fadogia agrestis stem in male albino rats, Asian J Androl, PMID 16281088

pubmed.ncbi.nlm.nih.gov · 2005

the foundational 5-day rat study; the entire testosterone-marketing edifice rests on this paper.

View Study

Yakubu, Akanji, Oladiji 2008 — Effects of aqueous extract of Fadogia agrestis stem on testicular function indices of male rats, J Ethnopharmacol, PMID 18023305

pubmed.ncbi.nlm.nih.gov · 2008

28-day follow-up showing irreversible testicular damage at 50-100 mg/kg.

View Study

Yakubu, Oladiji, Akanji 2009 — Mode of cellular toxicity of aqueous extract of Fadogia agrestis stem in male rat liver and kidney, Hum Exp Toxicol, PMID 19755438

pubmed.ncbi.nlm.nih.gov · 2009

lipid-peroxidation hepato/nephrotoxicity mechanism paper.

View Study

Kaliounji et al. 2024 — A Rare Case of Tongkat Ali-Induced Liver Injury, Cureus, PMC11032125

pmc.ncbi.nlm.nih.gov · 2024

first published Tongkat Ali hepatotoxicity case; relevant because Tongkat is the most common Fadogia stack-mate.

View Study

Owolabi 2023 — Effect of Fadogia cienkowskii ethanol root extract on semen parameters, testes, epididymis, liver, kidney of male albino rats, ScienceDirect

sciencedirect.com · 2023

adjacent-species toxicity corroboration.

View Study

Coalson et al. 2025 — Severe Biventricular Failure, ARDS, and DIC Linked to Fadogia Agrestis, Trimethylglycine, and Anastrozole (AJRCCM 211:A3862)

atsjournals.org · 2025

first published fatal case with Fadogia in the polypharmacy; American Thoracic Society 2025 meeting abstract.

View Source

Examine.com — Fadogia agrestis benefits, dosage, side effects

examine.com

independent academic-summary reference; declines to recommend dose due to safety uncertainty.

View Source

Huberman Lab AI clip — Is fadogia agrestis good for men?

ai.hubermanlab.com

Huberman's own statements on Fadogia and his recommended protocol.

View Source

Huberman Lab AI clip — Is fadogia agrestis safe?

ai.hubermanlab.com

Huberman's safety framing.

View Source

LiverTox NCBI Bookshelf — Tongkat Ali

ncbi.nlm.nih.gov

co-stack hepatotoxicity context.

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…